A GLP-1/GLP-2 dual agonist represented by the formula: R 1 -X*-U-R 2 wherein: R 1 is hydrogen (Hy), C 1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl; R 2 is NH 2 or OH; X* is a peptide of formula I: H-X2-EG-X5-F-X7-X8-E-X10-X11-TIL-X15-X16-X17-A-X19-X20-X21-FI-X24-WL-X27-X28-X29-KIT-X33 wherein: X2 is Aib or G X5 is T or S; X7 is T or S; X8 is S, E or D; X10 is L, M, V or Ψ; X11 is A, N or S; X15 is D or E; X16 is G, E, A or Ψ; X17 is Q, E, K, L or Ψ; X19 is A, V or S; X20 is R, K or Ψ; X21 is D, L or E; X24 is A, N or S; X27 is I, Q, K, H or Y; X28 is Q, E, A, H, Y, L, K, R or S; X29 is H, Y, K or Q; X33 is D or E; U is absent or a sequence of 1-15 residues each independently selected from K, k, E, A, T, I, L and Ψ; the molecule contains one and only one ψ, wherein Ψ is a residue of K, k, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula Z 1 - or Z 1 -Z 2 -, wherein Z 1 - is CH 3 -(CH 2) 10-22 - - or HOOC-(CH 2) 10-22 - -; and -Z 2 - is selected from -Z S1 -, -Z S1 -Z S2 -, -Z S2 -Z S1, -Z S2 -, -Z S3 -, -Z S1 Z S3 -, -Z S2 Z S3 -, -Z S3 Z S1 -, -Z S3 Z S2 -, -Z S1 Z S2 Z S3 -, -Z S1 Z S3 Z S2 -, -Z S2 Z S1 Z S3 -, -Z S2 Z S3 Z S1 -, -Z S3 Z S1 Z S2 -, -Z S3 Z S2 Z S1 -, Z S2 Z S3 Z S2 - wherein Z S1 is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl; Z S2 is - m - where m is 1, 2, or 3; and -Z S3 - is a peptide sequence of 1-6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G; and wherein at least one of X5 and X7 is T; or a pharmaceutically acceptable salt or solvate thereof. R 1 is hydrogen (Hy), C 1-4 alkyl (e.g. methyl), acetyl, formyl, benzoyl or trifluoroacetyl; R 2 is NH 2 or OH; X* is a peptide of formula I: H-X2-EG-X5-F-X7-X8-E-X10-X11-TIL-X15-X16-X17-A-X19-X20-X21-FI-X24-WL-X27-X28-X29-KIT-X33 wherein: X2 is Aib or G X5 is T or S; X7 is T or S; X8 is S, E or D; X10 is L, M, V or Ψ; X11 is A, N or S; X15 is D or E; X16 is G, E, A or Ψ; X17 is Q, E, K, L or Ψ; X19 is A, V or S; X20 is R, K or Ψ; X21 is D, L or E; X24 is A, N or S; X27 is I, Q, K, H or Y; X28 is Q, E, A, H, Y, L, K, R or S; X29 is H, Y, K or Q; X33 is D or E; U is absent or a sequence of 1-15 residues each independently selected from K, k, E, A, T, I, L and Ψ; the molecule contains one and only one ψ, wherein Ψ is a residue of K, k, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula Z 1 - or Z 1 -Z 2 -, wherein Z 1 - is CH 3 -(CH 2) 10-22 - - or HOOC-(CH 2) 10-22 - -; and -Z 2 - is selected from -Z S1 -, -Z S1 -Z S2 -, -Z S2 -Z S1, -Z S2 -, -Z S3 -, -Z S1 Z S3 -, -Z S2 Z S3 -, -Z S3 Z S1 -, -Z S3 Z S2 -, -Z S1 Z S2 Z S3 -, -Z S1 Z S3 Z S2 -, -Z S2 Z S1 Z S3 -, -Z S2 Z S3 Z S1 -, -Z S3 Z S1 Z S2 -, -Z S3 Z S2 Z S1 -, Z S2 Z S3 Z S2 - wherein Z S1 is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl; Z S2 is - m - where m is 1, 2, or 3; and -Z S3 - is a peptide sequence of 1-6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G; and wherein at least one of X5 and X7 is T; or a pharmaceutically acceptable salt or solvate thereof. X2 is Aib or G X5 is T or S; X7 is T or S; X8 is S, E or D; X10 is L, M, V or Ψ; X11 is A, N or S; X15 is D or E; X16 is G, E, A or Ψ; X17 is Q, E, K, L or Ψ; X19 is A, V or S; X20 is R, K or Ψ; X21 is D, L or E; X24 is A, N or S; X27 is I, Q, K, H or Y; X28 is Q, E, A, H, Y, L, K, R or S; X29 is H, Y, K or Q; X33 is D or E; U is absent or a sequence of 1-15 residues each independently selected from K, k, E, A, T, I, L and Ψ; the molecule contains one and only one ψ, wherein Ψ is a residue of K, k, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula Z 1 - or Z 1 -Z 2 -, wherein Z 1 - is CH 3 -(CH 2) 10-22 - - or HOOC-(CH 2) 10-22 - -; and -Z 2 - is selected from -Z S1 -, -Z S1 -Z S2 -, -Z S2 -Z S1, -Z S2 -, -Z S3 -, -Z S1 Z S3 -, -Z S2 Z S3 -, -Z S3 Z S1 -, -Z S3 Z S2 -, -Z S1 Z S2 Z S3 -, -Z S1 Z S3 Z S2 -, -Z S2 Z S1 Z S3 -, -Z S2 Z S3 Z S1 -, -Z S3 Z S1 Z S2 -, -Z S3 Z S2 Z S1 -, Z S2 Z S3 Z S2 - wherein Z S1 is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl; Z S2 is - m - where m is 1, 2, or 3; and -Z S3 - is a peptide sequence of 1-6 amino acid units independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G; and wherein at least one of X5 and X7 is T; or a pharmaceutically acceptable salt or solvate thereof.